Emerald Advisers Inc. PA decreased its stake in Amicus Therapeutics Inc. (NASDAQ:FOLD) by 44.3% during the second quarter, Holdings Channel reports. The institutional investor owned 1,056,583 shares of the biopharmaceutical company’s stock after selling 841,238 shares during the period. Emerald Advisers Inc. PA’s holdings in Amicus Therapeutics were worth $5,769,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently bought and sold shares of FOLD. M&T Bank Corp purchased a new position in Amicus Therapeutics during the first quarter valued at approximately $157,000. Squarepoint Ops LLC boosted its position in Amicus Therapeutics by 101.9% in the first quarter. Squarepoint Ops LLC now owns 83,600 shares of the biopharmaceutical company’s stock valued at $706,000 after buying an additional 42,200 shares in the last quarter. Pacad Investment Ltd. boosted its position in Amicus Therapeutics by 42.9% in the first quarter. Pacad Investment Ltd. now owns 83,990 shares of the biopharmaceutical company’s stock valued at $710,000 after buying an additional 25,231 shares in the last quarter. UBS Group AG boosted its position in Amicus Therapeutics by 37.7% in the first quarter. UBS Group AG now owns 88,282 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 24,155 shares in the last quarter. Finally, Wexford Capital LP purchased a new position in Amicus Therapeutics during the first quarter valued at approximately $1,095,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.
Amicus Therapeutics Inc. (NASDAQ:FOLD) traded up 2.66% on Friday, reaching $7.71. 1,542,875 shares of the company were exchanged. The firm’s market capitalization is $1.10 billion. Amicus Therapeutics Inc. has a 12-month low of $4.98 and a 12-month high of $11.78. The firm has a 50-day moving average of $7.21 and a 200 day moving average of $6.95.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.07. On average, equities analysts predict that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.
Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Leerink Swann reissued an “outperform” rating and set a $19.00 target price (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Finally, Chardan Capital set a $15.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $12.19.
In other news, insider Hung Do sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total value of $175,000.00. Following the transaction, the insider now owns 583,453 shares in the company, valued at $4,084,171. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Perceptive Advisors Llc sold 1,100,000 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $6.81, for a total transaction of $7,491,000.00. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.